Physician profile
Anand Chockalingam
NPI 1669409108
$2,570.36
in general payments reported to CMS, 2019-2025
19 companies · $826 in 2025
The $826 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $47.13 · 2021: $83.79 · 2022: $132 · 2023: $205 · 2024: $808 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,839.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $388.68 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $377.53 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $286.65 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Recor Medical INC | $251.95 | 2025 | Paradise Ultrasound Renal Denervation System |
| E.R. Squibb & Sons, L.L.C. | $247.59 | 2019-2023 | Camzyos |
| Kestra Medical Technology Services, INC. | $178.21 | 2024-2025 | Assure Wcd |
| Lilly USA, LLC | $117.70 | 2024 | Jardiance |
| Cvrx, INC. | $110.70 | 2025 | Barostim Neo System |
| Amgen INC. | $100.70 | 2019-2023 | Repatha |
| Penumbra, INC. | $91.06 | 2025 | Penumbra System |
| Astrazeneca Pharmaceuticals LP | $82.19 | 2019 | |
| Boston Scientific Corporation | $76.80 | 2019 | |
| Lantheus Medical Imaging, INC. | $68.84 | 2019-2025 | |
| Pfizer INC. | $54.60 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.18 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33.55 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $29.79 | 2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $19.89 | 2019 | |
| Merck Sharp & Dohme LLC | $16.75 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anand Chockalingam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.